enicepatide
AssetAlso CT-388, RO7795068
Activates GLP-1 and GIP receptors to support weight management.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 5
- Indications
- 5
- Trials
- 2
- Developers
Indications
5Obesity
Phase 3, Recruiting, NCT07670416, clinicaltrials.gov, 11 Oct 2026
Obesity or overweight
Phase 3, Recruiting, NCT07351045, clinicaltrials.gov, 16 Oct 2026
Overweight
Phase 3, Recruiting, NCT07670416, clinicaltrials.gov, 11 Oct 2026
2 more
In the full profile
- Targets and what it contains5
- Owner and partners3
- Trials5
- Evidence for its targets5
- Competitors12
- Aging relevance1
- Signals9
Every asset’s record: target, stage, trials and the evidence behind it.